No Data
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Announces Target Price $9
Mersana Therapeutics Is Maintained at Buy by Citigroup
Citi Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $5
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Chimerix (CMRX) and Mersana Therapeutics (MRSN)
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report